

Chapter 4

Coronary Physiology and Atherosclerosis

Edward R.M. O'Brien, MD • Howard J. Nathan, MD

Anatomy and Physiology of Blood Vessels

Normal Artery Wall
Endothelium

Determinants of Coronary Blood Flow

Perfusion Pressure and Myocardial Compression
Myocardial Metabolism
Neural and Humoral Control
Coronary Pressure-Flow Relations
Coronary Reserve
Transmural Blood Flow

Atherosclerosis

Arterial Wall Inflammation
Role of Lipoproteins in Lesion Formation

Pathophysiology of Coronary Blood Flow

Coronary Artery Stenoses and Plaque Rupture
Coronary Collateral Vessels
Pathogenesis of Myocardial Ischemia
Determinants of Myocardial Oxygen
Supply/Demand Ratio
Dynamic Stenosis
Coronary Steal

Summary

References

When caring for patients with coronary artery disease (CAD), the anesthesiologist must prevent or minimize myocardial ischemia by maintaining optimal conditions for perfusion of the heart. This goal can be achieved only with an understanding of the many factors that determine myocardial blood flow in both health and disease.

ANATOMY AND PHYSIOLOGY OF BLOOD VESSELS

The coronary vasculature has been traditionally divided into three functional groups: large conductance vessels visible on coronary angiography, which offer little resistance to blood flow; small resistance vessels ranging in size from about 250 to 10 μm in diameter; and veins. Although it has been taught that arterioles (precapillary vessels $< 50 \mu\text{m}$) account for most of the coronary resistance, studies indicate that, under resting conditions, 45% to 50% of total coronary vascular resistance resides in vessels larger than 100 μm in diameter. This may be due, in part, to the relatively great length of the small arteries.

Normal Artery Wall

The arterial lumen is lined by a monolayer of endothelial cells that overlies smooth muscle cells (Fig. 4-1). The inner layer of smooth muscle cells, known as the intima, is circumscribed by the internal elastic lamina. Between the internal elastic lamina




Figure 4-1 Normal human coronary artery of a 32-year-old woman. The intima (i) and media (m) are composed of smooth muscle cells. The adventitia (a) consists of a loose collection of adipocytes, fibroblasts, vasa vasorum, and nerves. The media is separated from the intima by the internal elastic lamina (*open arrow*) and the adventitia by the external elastic lamina (*solid arrow*). (Movat's pentachrome-stained slide, original magnification $\times 6.6$.)

and external elastic lamina is another layer of smooth muscle cells, the media. Outside the external elastic lamina is an adventitia that is sparsely populated by cells and microvessels of the vasa vasorum.

Endothelium

Although the vascular endothelium was once thought of as an inert lining for blood vessels, it is more accurately characterized as a very active, distributed organ with many biologic functions. It has synthetic and metabolic capabilities and contains receptors for a variety of vasoactive substances.

Endothelium-Derived Relaxing Factors

The first vasoactive endothelial substance to be discovered was prostacyclin (PGI_2), a product of the cyclooxygenase pathway of arachidonic acid metabolism (Box 4-1). The production of PGI_2 is activated by shear stress, pulsatility of flow, hypoxia, and a variety of vasoactive mediators. Upon production it leaves the endothelial cell and acts in the local environment to cause relaxation of the underlying smooth muscle or to inhibit platelet aggregation. Both actions are mediated by the stimulation of adenylyl cyclase in the target cell to produce cyclic adenosine monophosphate (cAMP).

It has been shown that many physiologic stimuli cause vasodilation by stimulating the release of a labile, diffusible, nonprostanoid molecule termed *endothelium-derived relaxing factor* (EDRF), now known to be nitric oxide (NO). NO is the basis of a widespread paracrine signal transduction mechanism whereby one cell type can modulate the behavior of adjacent cells of a different type.^{1,2} NO is a very small lipophilic molecule that can readily diffuse across biologic membranes and into the cytosol of nearby cells. The half-life of the molecule is less than 5 seconds so that only the local environment can be affected. NO is synthesized from the amino acid l-arginine by NO synthase (NOS). When NO diffuses into the cytosol of the target cell, it binds with the heme group of soluble guanylate

BOX 4-1 Endothelium-Derived Relaxing and Contracting Factors

Healthy endothelial cells have an important role in modulating coronary tone by producing:

Vascular Muscle-Relaxing Factors

- Prostacyclin
- Nitric oxide
- Hyperpolarizing factor

Vascular Muscle-Contracting Factors

- Prostaglandin H₂
- Thromboxane A₂
- Endothelin

BOX 4-2 Endothelial Inhibition of Platelets

Healthy endothelial cells have a role in maintaining the fluidity of blood by producing:

- Anticoagulant factors: protein C and thrombomodulin
- Fibrinolytic factor: tissue-type plasminogen activator
- Platelet inhibitory substances: prostacyclin and nitric oxide

cyclase, resulting in a 50- to 200-fold increase in production of cyclic guanosine monophosphate (cGMP), its second messenger. If the target cells are vascular smooth muscle cells, vasodilation occurs; if the target cells are platelets, adhesion and aggregation are inhibited.

It is likely that NO is the final common effector molecule of nitrovasodilators (including sodium nitroprusside and organic nitrates such as nitroglycerin). The cardiovascular system is in a constant state of active vasodilation that is dependent on the generation of NO. The molecule is more important in controlling vascular tone in veins and arteries compared with arterioles. Abnormalities in the ability of the endothelium to produce NO likely play a role in diseases such as diabetes, atherosclerosis, and hypertension. The venous circulation of humans seems to have a lower basal release of NO and an increased sensitivity to nitrovasodilators compared with the arterial side of the circulation.³

Endothelium-Derived Contracting Factors

Contracting factors produced by the endothelium include prostaglandin H₂, thromboxane A₂ (via cyclooxygenase), and the peptide endothelin. Endothelin is a potent vasoconstrictor peptide (100-fold more potent than norepinephrine).⁴

Endothelial Inhibition of Platelets

A primary function of endothelium is to maintain the fluidity of blood. This is achieved by the synthesis and release of anticoagulant (e.g., thrombomodulin, protein C), fibrinolytic (e.g., tissue-type plasminogen activator), and platelet inhibitory (e.g., PGI₂, NO) substances (Box 4-2). Mediators released from aggregating platelets stimulate the release of NO and PGI₂ from intact endothelium, which act together to increase blood flow and decrease platelet adhesion and

BOX 4-3 Determinants of Coronary Blood Flow

The primary determinants of coronary blood flow are:

- Perfusion pressure
- Myocardial extravascular compression
- Myocardial metabolism
- Neurohumoral control

aggregation, thereby flushing away microthrombi and maintaining the patency of the vessel.

DETERMINANTS OF CORONARY BLOOD FLOW

Under normal conditions, there are four major determinants of coronary blood flow: perfusion pressure, myocardial extravascular compression, myocardial metabolism, and neurohumoral control.

Perfusion Pressure and Myocardial Compression

Coronary blood flow is proportional to the pressure gradient across the coronary circulation (Box 4-3). This gradient is calculated by subtracting downstream coronary pressure from the pressure in the root of the aorta.

During systole, the heart throttles its own blood supply. The force of systolic myocardial compression is greatest in the subendocardial layers, where it approximates intraventricular pressure. Resistance due to extravascular compression increases with blood pressure, heart rate, contractility, and preload.

Although the true downstream pressure of the coronary circulation is likely close to the coronary sinus pressure, other choices may be more appropriate in clinical circumstances. The most appropriate measure of the driving pressure for flow is the average pressure in the aortic root during diastole. This can be approximated by aortic diastolic or mean pressure.

Myocardial Metabolism

Myocardial blood flow, like flow in the brain and skeletal muscle, is primarily under metabolic control. Even when the heart is cut off from external control mechanisms (neural and humoral factors), its ability to match blood flow to its metabolic requirements is almost unaffected. Because coronary venous oxygen tension is normally 15 to 20 mm Hg, there is only a small amount of oxygen available through increased extraction. A major increase in cardiac oxygen consumption ($M\dot{V}O_2$), beyond the normal resting value of 80 to 100 mL O_2 /100 g of myocardium, can occur only if oxygen delivery is increased by augmentation of coronary blood flow. Normally, flow and metabolism are closely matched so that over a wide range of oxygen consumption coronary sinus oxygen saturation changes little.⁵

Hypotheses of metabolic control propose that vascular tone is linked either to a substrate that is depleted, such as oxygen or adenosine triphosphate (ATP), or to the accumulation of a metabolite such as carbon dioxide (CO_2) or hydrogen ion (Box 4-4). Adenosine has been proposed in both categories.

BOX 4-4 Myocardial Metabolism

Several molecules have been proposed as the link between myocardial metabolism and myocardial blood flow, including:

- Oxygen
- Carbon dioxide
- Adenosine

Current evidence suggests that a combination of local factors act together, each with differing importance during rest, exercise, and ischemia, to match myocardial oxygen delivery to demand.

Neural and Humoral Control

Coronary Innervation

The heart is supplied with branches of the sympathetic and parasympathetic divisions of the autonomic nervous system. Large and small coronary arteries and veins are richly innervated. The sympathetic nerves to the heart and coronary vessels arise from the superior, middle, and inferior cervical sympathetic ganglia and the first four thoracic ganglia. The stellate ganglion (formed when the inferior cervical and first thoracic ganglia merge) is a major source of cardiac sympathetic innervation. The vagi supply the heart with efferent cholinergic nerves.

Parasympathetic Control

Vagal stimulation causes bradycardia, decreased contractility, and lower blood pressure. The resultant fall in $M\dot{V}O_2$ causes a metabolically-mediated coronary vasoconstriction. The direct effect of activation of cholinergic receptors on coronary vessels is vasodilation. These direct effects can be abolished by atropine.

β -Adrenergic Coronary Dilation

β -Receptor activation causes dilation of both large and small coronary vessels even in the absence of changes in blood flow.

α -Adrenergic Coronary Constriction

The direct effect of sympathetic stimulation is coronary vasoconstriction, which is in competition with the metabolically-mediated dilation of exercise or excitement. Whether adrenergic coronary constriction is powerful enough to further diminish blood flow in ischemic myocardium or if it can have some beneficial effect in the distribution of myocardial blood flow is controversial.

Coronary Pressure-Flow Relations

Autoregulation

Autoregulation is the tendency for organ blood flow to remain constant despite changes in arterial perfusion pressure. Autoregulation can maintain flow to myocardium served by stenotic coronary arteries despite low perfusion pressure distal to the obstruction. This is a local mechanism of control and can be observed in isolated, denervated hearts. If $M\dot{V}O_2$ is fixed, coronary blood flow remains relatively constant between mean arterial pressures of 60 to 140 mm Hg.

Coronary Reserve

Myocardial ischemia causes intense coronary vasodilation. Following a 10- to 30-second coronary occlusion, restoration of perfusion pressure is accompanied by a marked increase in coronary flow. This large increase in flow, which can be five or six times resting flow in the dog, is termed *reactive hyperemia*. The repayment volume is greater than the debt volume. There is, however, no overpayment of the oxygen debt because oxygen extraction falls during the hyperemia. The presence of high coronary flows when coronary venous oxygen content is high suggests that mediators other than oxygen are responsible for this metabolically-induced vasodilation. The difference between resting coronary blood flow and peak flow during reactive hyperemia represents the autoregulatory coronary flow reserve: the further capacity of the arteriolar bed to dilate in response to ischemia.⁶

Transmural Blood Flow

It is well known that when coronary perfusion pressure is inadequate, the inner one third to one fourth of the left ventricular wall is the first region to become ischemic or necrotic.⁷ This increased vulnerability of the subendocardium may be due to an increased demand for perfusion or a decreased supply, compared with the outer layers.

If coronary pressure is gradually reduced, autoregulation is exhausted and flow decreases in the inner layers of the left ventricle before it begins to decrease in the outer layers (Fig. 4-2). This indicates that there is less flow reserve in the subendocardium than in the subepicardium.

Three mechanisms have been proposed to explain the decreased coronary reserve in the subendocardium: differential systolic intramyocardial pressure, differential diastolic intramyocardial pressure, and interactions between systole and diastole.




Figure 4-2 Pressure-flow relationships of the subepicardial and subendocardial thirds of the left ventricle in anesthetized dogs. In the subendocardium, autoregulation is exhausted and flow becomes pressure dependent when pressure distal to a stenosis falls below 70 mm Hg. In the subepicardium, autoregulation persists until perfusion pressure falls below 40 mm Hg. Autoregulatory coronary reserve is less in the subendocardium. (Redrawn from Guyton RA, McClenathan JH, Newman GE, Michaelis LL: Significance of subendocardial ST segment elevation caused by coronary stenosis in the dog. *Am J Cardiol* 40:373, 1977.)

ATHEROSCLEROSIS

The atherosclerotic lesion consists of an excessive accumulation of smooth muscle cells in the intima, with quantitative and qualitative changes in the noncellular connective tissue components of the artery wall and intracellular and extracellular deposition of lipoproteins and mineral components (e.g., calcium). By definition, *atherosclerosis* is a combination of “atherosis” and “sclerosis.” The latter term, *sclerosis*, refers to the hard collagenous material that accumulates in lesions and is usually more voluminous than the pultaceous “gruel” of the atheroma (Fig. 4-3).

Stary noted that the earliest detectable change in the evolution of coronary atherosclerosis in young people was the accumulation of intracellular lipid in the subendothelial region, giving rise to lipid-filled macrophages or “foam cells.”⁸ Grossly, a collection of foam cells may give the artery wall the appearance of a “fatty streak.” In general, fatty streaks are covered by a layer of intact endothelium and are not characterized by excessive smooth muscle cell accumulation. At later stages of atherogenesis, extracellular lipoproteins accumulate in the musculoelastic layer of the intima, eventually forming an avascular core of lipid-rich debris that is separated from the central arterial lumen by a fibrous cap of collagenous material. Foam cells are not usually seen deep within the atheromatous core but are frequently found at the periphery of the lipid core.

Arterial Wall Inflammation

A number of studies have demonstrated the presence of monocytes/macrophages and T lymphocytes in the arteries of not only advanced lesions but also early atherosclerotic lesions of young adults.⁹ Moreover, in experimental atherosclerosis, leukocyte infiltration into the vascular wall is known to precede smooth muscle cell hyperplasia. Once inside the artery wall, mononuclear cells may play several important roles in lesion development. For example, monocytes may transform into macrophages




Figure 4-3 Atherosclerotic human coronary artery of an 80-year-old man. There is severe narrowing of the central arterial lumen (L). The intima consists of a complex collection of cells, extracellular matrix (M), and a necrotic core with cholesterol (C) deposits. Rupture of plaque microvessels has resulted in intraplaque hemorrhage (arrow) at the base of the necrotic core. (Movat’s pentachrome-stained slide, original magnification $\times 40$.)

and become involved in the local oxidation of low-density lipoproteins (LDLs) and accumulation of oxidized LDLs. Alternatively, macrophages in the artery wall may act as a rich source of factors that, for example, promote cell proliferation, migration, or the breakdown of local tissue barriers. The latter process of local tissue degradation may be very important for the initiation of acute coronary artery syndromes because loss of arterial wall integrity may lead to plaque fissuring or rupture.

Role of Lipoproteins in Lesion Formation

The clinical and experimental evidence linking dyslipidemias with atherogenesis is well established and need not be reviewed here. However, the exact mechanisms by which lipid moieties contribute to the pathogenesis of atherosclerosis remain elusive. Although the simple concept of cholesterol accumulating in artery walls until flow is obstructed may be correct in certain animal models, this theory is not correct for human arteries.

One of the major consequences of cholesterol accumulation in the artery wall is thought to be the impairment of endothelial function. The endothelium is more than a physical barrier between the bloodstream and the artery wall. Under normal conditions, the endothelium is capable of modulating vascular tone (e.g., via NO), thrombogenicity, fibrinolysis, platelet function, and inflammation. In the presence of traditional risk factors, particularly dyslipidemias, these protective endothelial functions are reduced or lost. A number of clinical studies demonstrate dramatic improvements in endothelial function, as well as cardiovascular morbidity and mortality, with the use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or “statins.”¹⁰

PATHOPHYSIOLOGY OF CORONARY BLOOD FLOW

Coronary Artery Stenoses and Plaque Rupture

Coronary atherosclerosis is a chronic disease that develops over decades, remaining clinically silent for prolonged periods of time (Box 4-5). Clinical manifestations of CAD occur when the atherosclerotic plaque mass encroaches on the vessel lumen and obstructs coronary blood flow, causing angina. Alternatively, cracks or fissures may develop in the atherosclerotic lesions and result in acute thromboses that cause unstable angina or myocardial infarction.

Patients with stable angina typically have lesions with smooth borders on angiography. Only a minority of coronary lesions are concentric, with most having a complex geometry varying in shape over their length. Eccentric stenoses, with a remaining pliable, musculoelastic arc of normal wall, can vary in diameter and resistance

BOX 4-5 Pathophysiology of Coronary Blood Flow

- In the majority of patients experiencing a myocardial infarction, the coronary occlusion occurs at the site of less than 50% stenosis.
- Plaque rupture leads to incremental growth of coronary stenoses and can cause coronary events.
- Plaque rupture occurs at the shoulder of the plaque where inflammatory cells are found.

in response to changes in vasomotor tone or intraluminal pressure. The majority of human coronary stenoses are compliant. The intima of the normal portion of the vessel wall is often thickened, making endothelial dysfunction probable. In contrast, patients with unstable angina usually have lesions characterized by overhanging edges, scalloped or irregular borders, or multiple irregularities. These complicated stenoses likely represent ruptured plaque or partially occlusive thrombus or both.¹¹ Superficial intimal injury (plaque erosions) and intimal tears of variable depth (plaque fissures) with overlying microscopic mural thrombosis are commonly found in atherosclerotic plaques. In the absence of obstructive luminal thrombosis, these intimal injuries do not cause clinical events. However, disruption of the fibrous cap, or plaque rupture, is a more serious event that typically results in the formation of clinically significant arterial thromboses. From autopsy studies it is known that rupture-prone plaques tend to have a thin, friable fibrous cap. The site of plaque rupture is thought to be the shoulder of the plaque, where substantial numbers of mononuclear inflammatory cells are commonly found.¹² The mechanisms responsible for the local accumulation of these cells at this location in the plaque are unknown; presumably, monocyte chemotactic factors, the expression of leukocyte cell adhesion molecules, and specific cytokines are involved. Moreover, macrophages in plaques have been shown to express factors such as stromelysin, which promote the breakdown of the extracellular matrix and thereby weaken the structural integrity of the plaque.

Coronary Collateral Vessels

Coronary collateral vessels are anastomotic connections, without an intervening capillary bed, between different coronary arteries or between branches of the same artery. In the normal human heart, these vessels are small and have little or no functional role. In patients with CAD, well-developed coronary collateral vessels may play a critical role in preventing death and myocardial infarction. Individual differences in the capability of developing a sufficient collateral circulation is a determinant of the vulnerability of the myocardium to coronary occlusive disease.¹³

It has been estimated that, in humans, perfusion via collateral vessels can equal perfusion via a vessel with a 90% diameter obstruction. Although coronary collateral flow can be sufficient to preserve structure and resting myocardial function, muscle dependent on collateral flow usually becomes ischemic when oxygen demand rises above resting levels. It is possible that evidence from patients with angina underestimates collateral function of the population of all patients with CAD.¹⁴

Pathogenesis of Myocardial Ischemia

Ischemia is the condition of oxygen deprivation accompanied by inadequate removal of metabolites consequent to reduced perfusion. Clinically, myocardial ischemia is a decrease in the blood flow supply/demand ratio resulting in impaired function. There is no universally accepted “gold standard” for the presence of myocardial ischemia. In practice, symptoms, anatomic findings, and evidence of myocardial dysfunction must be combined before concluding that myocardial ischemia is present.

Determinants of Myocardial Oxygen Supply/Demand Ratio

An increase in myocardial oxygen requirement beyond the capacity of the coronary circulation to deliver oxygen results in myocardial ischemia (Box 4-6). This is the most common mechanism leading to ischemic episodes in chronic stable angina

BOX 4-6 *Determinants of Myocardial Oxygen Supply/Demand Ratio*

The major determinants of myocardial oxygen consumption are:

- Heart rate
- Myocardial contractility
- Wall stress (chamber pressure \times radius/wall thickness)

and during exercise testing. Intraoperatively, the anesthesiologist must measure and control the determinants of myocardial oxygen consumption and protect the patient from “demand” ischemia. The major determinants of myocardial oxygen consumption are heart rate, myocardial contractility, and wall stress (chamber pressure \times radius/wall thickness).

An increase in heart rate can reduce subendocardial perfusion by shortening diastole. Coronary perfusion pressure may fall due to reduced systemic pressure or increased left ventricular end-diastolic pressure. With the onset of ischemia, perfusion may be further compromised by delayed ventricular relaxation (decreased subendocardial perfusion time) and decreased diastolic compliance (increased left ventricular end-diastolic pressure). Anemia and hypoxia can also compromise delivery of oxygen to the myocardium.

Dynamic Stenosis

Patients with CAD can have variable exercise tolerance during the day and between days. Ambulatory monitoring of the ECG has demonstrated that ST-segment changes indicative of myocardial ischemia, in the absence of changes in oxygen demand, are common.¹⁵ These findings are explained by variations over time in the severity of the obstruction to blood flow imposed by coronary stenoses.

Although the term *hardening of the arteries* suggests rigid, narrowed vessels, in fact most stenoses are eccentric and have a remaining arc of compliant tissue. A modest amount (10%) of shortening of the muscle in the compliant region of the vessel can cause dramatic changes in lumen caliber. This was part of Prinzmetal’s original proposal to explain coronary spasm. Maseri and associates¹⁶ suggest that the term *spasm* be reserved for “situations where coronary constriction is both focal, is sufficiently profound to cause transient coronary occlusion, and is responsible for reversible attacks of angina at rest” (i.e., variant angina).

Coronary Steal

Steal occurs when the perfusion pressure for a vasodilated vascular bed (in which flow is pressure dependent) is lowered by vasodilation in a parallel vascular bed, both beds usually being distal to a stenosis.¹⁷ Two kinds of coronary steal are illustrated: collateral and transmural (Fig. 4-4).

Collateral steal in which one vascular bed (R_3), distal to an occluded vessel, is dependent on collateral flow from a vascular bed (R_2) supplied by a stenotic artery is diagrammed in Figure 4-4A. Because collateral resistance is high, the R_3 arterioles are dilated to maintain flow in the resting condition (autoregulation). Dilation of the R_2 arterioles increases flow across the stenosis R_1 and decreases pressure P_2 . If R_3 resistance cannot further decrease sufficiently, flow there decreases, producing or worsening ischemia in the collateral-dependent bed.




Figure 4-4 Conditions for coronary steal between different areas of the heart (collateral steal [A]) and between the subendocardial and the subepicardial layers of the left ventricle (transmural steal [B]). See text for detailed description. R_1 = stenosis resistance; P_1 = aortic pressure; P_2 = pressure distal to the stenosis; R_2 and R_3 = resistance of autoregulating and pressure-dependent vascular beds, respectively. (From Epstein SE, Cannon RO, Talbot TL: Hemodynamic principles in the control of coronary blood flow. *Am J Cardiol* 56:4E, 1985.)

Transmural steal is illustrated in Figure 4-4B. Normally, vasodilator reserve is less in the subendocardium. In the presence of a stenosis, flow may become pressure dependent in the subendocardium while autoregulation is maintained in the subepicardium.

SUMMARY

- To safely care for patients with coronary artery disease in the perioperative period, the clinician must understand how the coronary circulation functions in health and disease.
- Coronary endothelium modulates myocardial blood flow by producing factors that relax or contract the underlying vascular smooth muscle.
- Vascular endothelial cells help maintain the fluidity of blood by elaborating anticoagulant, fibrinolytic, and antiplatelet substances.
- One of the earliest changes in coronary artery disease, preceding the appearance of stenoses, is the loss of the vasoregulatory and antithrombotic functions of the endothelium.
- The mean systemic arterial pressure and not the diastolic pressure may be the most useful and reliable measure of coronary perfusion pressure in the clinical setting.
- Although sympathetic activation increases myocardial oxygen demand, activation of α -adrenergic receptors causes coronary vasoconstriction.
- It is unlikely that one substance alone (e.g., adenosine) provides the link between myocardial metabolism and myocardial blood flow under a variety of conditions.
- As coronary perfusion pressure decreases, the inner layers of myocardium nearest the left ventricular cavity are the first to become ischemic and display impaired relaxation and contraction.
- The progression of an atherosclerotic lesion is similar to the process of wound healing.
- Lipid-lowering therapy can help restore endothelial function and prevent coronary events.

REFERENCES

1. Ignarro LJ: Nitric oxide: A novel signal transduction mechanism for transcellular communication. *Hypertension* 16:477, 1990
2. Lincoln TM, Dey N, Sellak H: Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: From the regulation of tone to gene expression. *J Appl Physiol* 91:1421, 2001
3. Harrison DG, Cai H: Endothelial control of vasomotion and nitric oxide production. *Cardiol Clin* 21:289, 2003
4. Goodwin AT, Yacoub MH: Role of endogenous endothelin on coronary flow in health and disease. *Coron Artery Dis* 12:517, 2001
5. Feigl EO: Coronary physiology. *Physiol Rev* 63:1, 1983
6. Kern MJ: Coronary physiology revisited: Practical insights from the cardiac catheterization laboratory. *Circulation* 101:1344, 2000
7. Hoffman JIE: Transmural myocardial perfusion. *Prog Cardiovasc Dis* 29:429, 1987
8. Stary HC: Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. *Arteriosclerosis* 9(suppl 1):I-19, 1989
9. Katsuda S, Boyd HC, Fligner C, et al: Human atherosclerosis: Immunocytochemical analysis of the cell composition of lesions of young adults. *Am J Pathol* 140:907, 1992
10. Treasure CB, Klein JL, Weintraub WS: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. *N Engl J Med* 332:481, 1995
11. Pasterkamp G, de Kleijn D, Borst C: Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: Potential mechanisms and clinical implications. *Cardiovasc Res* 45:843, 2000
12. Van der Wal AC, Becker AE, van der Loos CM, et al: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaque is characterized by an inflammatory process irrespective of the dominant plaque morphology. *Circulation* 89:36, 1994
13. Koerselman J, van der Graf Y, De Jaegere PP, et al: Coronary collaterals: An important and underexposed aspect of coronary artery disease. *Circulation* 107:2507, 2003
14. Fujita M, Tambara K: Recent insights into human coronary collateral development. *Heart* 90:246, 2004
15. Stone PH: Mechanisms of silent myocardial ischemia: Implications for selection of optimal therapy. *Adv Cardiol* 37:328, 1990
16. Maseri A, Newman C, Davies G: Coronary vasomotor tone: A heterogeneous entity. *Eur Heart J* 10(suppl F):2, 1989
17. Konidala S, Gutterman DD: Coronary vasospasm and the regulation of coronary blood flow. *Prog Cardiovasc Dis* 46:349, 2004